FFPE Tips and Tricks –
Join our webinar series
August 18–27

Let’s work to
conquer cancer.



Join the QIAGEN
Cancer Research Community

Why is cancer research
important to you?

Accelerate Your Cancer Research

Despite great progress made by scientists and physicians dedicated to cancer research, a lot of increasingly complex questions remain to be answered – to discover new ways to prevent, detect and treat cancer.

You can quickly gain answers to your questions in cancer research, if you rely on our expertise in all cancer sample types and analytes – from discovery to diagnostics. We provide Sample to Insight solutions to advance your research, accelerate your journey to insights and help to conquer cancer. Join our community and let’s do it together …


"The biggest challenges that we face are the quality of DNA from FFPE samples, finding DNA long enough to fit our system, as well as being able to pull out the T-cell receptors for sequencing. We are using QIAGEN for all of our extractions, whether its DNA, RNA, or T-cell RNA. It’s going through the QIAGEN kit fully automated with the QIAcube."

Brandon Mistretta

Researcher, University of Houston

“My team develops sample processing technologies to make it quicker and easier for researchers to discover and verify biomarkers. Liquid biopsy is non-invasive and has huge potential, but a lack of standardized and robust solutions obstruct its widespread adoption. We're helping to overcome roadblocks at each step of the process and to speed up the application of liquid biopsy in cancer research. We are pleased to be paving the way to liquid biopsy – leading to new insights and breakthroughs in non-invasive cancer research.”

Dr. Kerstin Steinert

Vice President Product Development & Research Services

"We analyze CTCs, EVs and cfDNA from a minimal blood volume. We figured out a workflow to analyze all of these materials from one blood draw. In one workflow branch, we wanted to use the remaining mRNA-depleted CTC lysate for isolation of genomic DNA from CTCs – it was challenging, and I am proud to say that we managed to establish this workflow as well. We can now identify actionable targets, and I am excited to see the sequencing results."

Corinna Keup

Researcher, University of Essen

“I am proud to be working with a team of technology experts to support scientists with the tools, solutions and expertise necessary to advance their research and accelerate their journey to valuable insights. QIAGEN empowers cancer researchers, with trusted and innovative solutions, to better understand critical biological mechanisms regulating the development, invasion and metastasis of cancers, and for discovery of RNA biomarkers in cancer.”

Jonathan M. Shaffer

Associate Director NGS Assay Technologies

“We partnered with QIAGEN and were able to put 37 [pancreatic cancer predisposition] genes on our panel, and we found a tremendous conversion rate. What I mean by that is the percentage of target genes that actually gave us back good results – so we’re over 99.6% efficiency on this panel. And we’ve not seen anything remotely like that with any other technology.”

Dr. Fergus Couch

Mayo Clinic

“We are constantly looking for new ways to create solutions that will help advance the understanding of genomic changes that cause a cell to become cancerous and what role the immune system plays. For example, we saw molecular barcodes as a potential game changer for next-generation sequencing. Our goal is to enable you to speed up your cancer genomics research and accelerate your journey to valuable insights.”

Dr. Yexun (”Bill”) Wang

Vice President R&D, Frederick, MD

Consortia and initiatives – we're working together

QIAGEN participates in numerous renowned international consortia, grant projects and initiatives that strive to improve global healthcare.  They extend and access networks and infrastructures – and stimulate exchange between all relevant stakeholders – from science, medicine and government.
Our active role in consortia  and initiatives keeps QIAGEN at the forefront of scientific findings and developments.

Cancer ID – a new way to track cancer

SPIDIA4P – better diagnosis and medical research

CBmed – biomarker identification, validation and research

EASI-Genomics – cutting-edge DNA sequencing technologies

EU-STANDS4PM – standards for in silico approaches in personalized medicine

Sign up for our Cancer Research Community to access exclusive Science Talks, podcasts and live events.

Social Sharing